Pamela Hay provides interim management and advisory services to biotech companies that are seeking to complete significant partnering or financing transactions. She has taken on acting CEO or CBO roles and served as a senior business advisor to management and investors during transition and growth phases. In these roles, she often leads the planning and negotiation of strategic transactions.
She is a founding partner of Red Sky with 30 years of executive or advisory roles at more than 20 biotech companies spanning the start-up through Phase 2 product development stages in multiple therapeutic indications. Her recent Red Sky assignments have included serving as co-CEO of Harbour Antibodies where she led its sale to Harbour Biomed, lead business negotiator for Luc Therapeutics in its Novartis CNS deal and interim CBO for Nimbus Therapeutics.
In addition to her role at Red Sky, Pamela is co-founder and President of Visgo Therapeutics, a start-up company developing products to treat joint diseases. Previously, Pamela was Chief Commercial Officer of Domantis Ltd, a Cambridge UK biotech company, sold to GSK for $450m in 2007 and was SVP, Corporate Development at Dyax Corp, where she designed and implemented the company’s broad-based licensing and partnering programs for phage display IP and technology. Her earlier positions include General Counsel of T Cell Sciences and Corporate Attorney at Biogen.
Pamela has a BA in Biology from Cornell University’s School of Arts and Sciences, and a JD from the University of Wisconsin School of Law.